Incyte Corporation has recently announced the results of Novartis-sponsored Phase III clinical trials REACH2 evaluating its candidate Ruxolitinib (Jakafi) in patients suffering from steroid-refractory acute graft-versus-host disease (GvHD). Graft versus host disease (GvHD), as defined by the National Cancer Institute (NCI), is a disease in which cells from a donated stem cell graft attack the normal tissues of the receiver patient.
The trials showed a consistent safety profile of ruxolitinib. The drug is an FDA-approved first-in-class JAK1/JAK2 inhibitor indicated for the treatment of polycythemia vera (PV), myelofibrosis (MF), including primary MF, post-polycythe...
